Bisphosphonates and Denosumab, the widely-used long-term treatment of osteolytic bone diseases and bone metastasis, were reported to exert direct and indirect anti-tumor effects, including inhibition of tumor cell proliferation and adhesion, reduction tumor cells secrete factors that increase RANKL expression, enhancement of immune surveillance, and prevention of angiogenesis (33–35). The gene discussed is TNFSF11; the disease is metastasis.